Due to these data Finland, on 12 October 1998, requested that the CPMP, under article 12 of Council Directive 75/ 319/ EEC as amended, give an opinion on whether there is an unfavourable benefit/ risk ratio for vigabatrin, especially in relation to its potential to induce serious visual field defects.